Identifying Maturity-onset Diabetes of the Young in Emirati Patients
Launched by UNITED ARAB EMIRATES UNIVERSITY · Oct 14, 2022
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a type of diabetes called Maturity-onset Diabetes of the Young (MODY) in Emirati patients. MODY is a genetic form of diabetes that usually affects younger people, typically under 35 years old, and is often misdiagnosed as type 1 or type 2 diabetes. This study aims to find out how common MODY is among young Emirati patients and to test the effectiveness of a risk calculator that can help identify those who may have this condition. Researchers want to ensure that people with MODY are correctly diagnosed so they can avoid unnecessary treatments like insulin injections.
To be eligible for this study, participants must be Emirati individuals aged 11 and older who have been diagnosed with type 1 or type 2 diabetes before the age of 40. They should have visited Tawam hospital within the last year and have no history of severe obesity, secondary diabetes, or specific markers that indicate type 1 diabetes. If you qualify and choose to participate, you can expect to undergo assessments that may help clarify your diabetes type and contribute to our understanding of MODY in the Emirati population. This study is important because it could lead to better diagnosis and treatment options for young people with diabetes in the UAE.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 11; both male or female, Emirati patients only
- • Diagnosed to have Type 1 or Type 2 Diabetes Mellitus diagnosed before the age of 40 and after the age of 6 months.
- • Attended Tawam hospital during the last 1 year.
- • All previous antibodies testing being negative.
- • Absence of ketoacidosis / significant ketosis in the past medical records
- Exclusion Criteria:
- • BMI of 40 or above (class 3 / severe obesity)
- • History of Secondary diabetes (e.g. Diabetes following pancreatitis)
- • Absent/Decreased C-peptide activity suggestive of Type 1 Diabetes
About United Arab Emirates University
United Arab Emirates University (UAEU) is a leading academic institution dedicated to advancing research and innovation in the region. As a prominent clinical trial sponsor, UAEU leverages its robust academic and scientific resources to conduct rigorous clinical research aimed at improving healthcare outcomes. The university fosters collaboration between multidisciplinary teams, encompassing researchers, healthcare professionals, and industry partners, to address pressing health challenges. Committed to ethical standards and regulatory compliance, UAEU aims to contribute to the global body of medical knowledge while enhancing the quality of care within the UAE and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Adnan Agha
Principal Investigator
United Arab Emirates University, College of Medicine & Health Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials